- Open
- 208.00
- High
- 213.40
- Low
- 206.20
- Close
- 211.00
- Change
- +2.80 (1.35%)
- Volume
- 5,321,908
⌘K
| 13 Apr 2026 | 12:00:00 | Professor Constantin Coussios steps down |
| 9 Apr 2026 | 07:00:07 | Capital Markets Day |
| 17 Mar 2026 | 13:00:00 | Notice of AGM |
| 17 Mar 2026 | 11:00:01 | Director/PDMR Shareholding |
| 10 Mar 2026 | Convatec Group Plc 2025 Annual Report | |
| 10 Mar 2026 | Annual Report and Accounts for the year ending 31 December 2025 | |
| 11 Mar 2025 | Convatec Group Plc 2024 Annual Report and Accounts |
ConvaTec is a worldwide provider of medical products and technologies that specialize in treating chronic conditions. They are leaders in advanced wound care, ostomy care, continence and critical care, and infusion care.
| 13 Apr 2026 | 12:00:00 | Professor Constantin Coussios steps down |
| 9 Apr 2026 | 07:00:07 | Capital Markets Day |
| 17 Mar 2026 | 13:00:00 | Notice of AGM |
| 17 Mar 2026 | 11:00:01 | Director/PDMR Shareholding |
| 10 Mar 2026 | Convatec Group Plc 2025 Annual Report | |
| 10 Mar 2026 | Annual Report and Accounts for the year ending 31 December 2025 | |
| 11 Mar 2025 | Convatec Group Plc 2024 Annual Report and Accounts |
ConvaTec is a worldwide provider of medical products and technologies that specialize in treating chronic conditions. They are leaders in advanced wound care, ostomy care, continence and critical care, and infusion care.
| 12 Mar 2026 |
| 14:30:00 |
| Director/PDMR Shareholding |
| 25 Feb 2026 |
| Health Care Roundup: Market Talk |
| 24 Feb 2026 | Convatec stars as FTSE 100 closes with little change |
| 24 Feb 2026 | Convatec rallies on upgraded growth targets |
| 24 Feb 2026 | ConvaTec climbs after upgrading medium-term outlook |
| 12 Mar 2026 |
| 14:30:00 |
| Director/PDMR Shareholding |
| 25 Feb 2026 |
| Health Care Roundup: Market Talk |
| 24 Feb 2026 | Convatec stars as FTSE 100 closes with little change |
| 24 Feb 2026 | Convatec rallies on upgraded growth targets |
| 24 Feb 2026 | ConvaTec climbs after upgrading medium-term outlook |